Roszdravnadzor has registered the first medical decision-making assistance system in the Russian Federation "Celsus" using artificial intelligence technologies for use in screening for breast cancer (mammography) and chest pathologies (fluorography).

The system for the analysis of medical radiographic images using artificial intelligence "Celsus" (LLC "Medical Screening Systems", a member of the Association "NBMZ") was the first in the Russian Federation to receive a registration certificate for a medical device for radiology in the areas of mammography and fluorography (risk class 3 in accordance with the order of the Ministry of Health of the Russian Federation No. 686n of July 7, 2020). The registration certificate confirms the quality, efficiency and safety of the solution.

Celsus – a system for helping medical decision-making (DSS) in radiology, is included in the register of domestic software. The platform recognizes the presence of benign or malignant changes in X-ray images, indicates their location, and then interprets the results according to international standards.

Artem Kapninsky, Commercial Director of Medical Screening Systems LLC: "Our product has proven its compliance with the current requirements for quality, safety and efficiency. Even today, doctors together with Celsus save people's lives. Of course, artificial intelligence cannot become a full-fledged replacement for a specialist, but it greatly simplifies the process of making a diagnosis, allowing you to buy time and detect cancer as early as possible, and start treatment in a timely manner."

Oleg Bronov, PhD, Executive Director of the Russian Society of Radiologists and Radiologists (RORR): "This is great news! The system of medical decision-making "Celsus" is a high-quality product, and the capabilities of the system allow you to use it not only at the stage of screening studies, but also to apply it in the practice of polyclinics and hospitals, which was confirmed by a joint clinical study. The system allows you not only to save the doctor's time to search for pathological changes, but also to double-check, conduct an audit, which allows you to increase the accuracy of the diagnosis. Such systems already allow us to reach a new level of patient examination."

The use of "Celsus" in practical work during screening will minimize the risks associated with the" human factor", compensate for the lack of primary care personnel, and increase the detection of cancer in the early stages.

Deputy Minister of Health of the Kaluga Region Alexander Korolev: "Celsus was the first solution, thanks to which doctors really felt the benefits of modern technologies in the field of artificial intelligence, both in reducing the time for diagnosis, and in the form of an objective assistant that insures against mistakes. The region is already ready to use the service."

The effectiveness of the Celsus SPVR was confirmed during pilot and commercial tests in a number of regions, as well as an experiment of the Moscow Department of Health on the use of artificial intelligence services in radiology. As a result of the experiment, "Celsus" was recognized as one of the leaders in the number and accuracy of processed images.

According to the chief freelance specialist in radiation and instrumental diagnostics of the Department of Health of the City of Moscow and the Ministry of Health of the Russian Federation for the Central Federal District, director of the Center for Diagnostics and Telemedicine Sergey Morozov, "Celsus" has already actually passed the phase of post-registration tests of medical artificial intelligence as part of the Moscow experiment on computer vision: "Before connecting to the general information circuit of ERIS EMIAS, the service was validated on independent sets of studies in order to check the diagnostic accuracy in the "field" conditions, sensitivity and specificity of algorithms. Then, during 2020, "Celsus" was used in real clinical practice by Moscow radiologists. This allowed the developers to get expert feedback from medical users and identify weaknesses for further training of the service."

"The Medsi Clinical Research Center was among the first in Russia to successfully test medical software that uses artificial intelligence technologies –" says Anton Silin, Deputy Medical Director for Radiation and Instrumental Diagnostics of the Medsi Group of Companies. " Despite the strict conditions for conducting clinical trials, Celsus has demonstrated a high level of accuracy, which makes it a real assistant in the daily work of a radiologist. Digitalization is one of the priority vectors of Medsi's development, and we are pleased that new high-quality products are entering the market, increasing the quality and speed of medical services."

"High-quality and accurate diagnosis at an early stage significantly increases the effectiveness of therapy and, as a result,the likelihood of a favorable prognosis for patients with cancer. That is why diagnostic solutions based on artificial intelligence are so popular today. The Celsus system is one of the participants of the iLab startup accelerator, organized by AstraZeneca together with the Skolkovo Foundation, in which we will be able to evaluate the best way to integrate the system into clinical practice, "said Eugenia Logacheva, AstraZeneca's Medical Director for oncology.

In 2020, the company attracted investments from the NTI Venture fund in the amount of 180 million for the development of sales and technological improvement of the platform. At the moment, the solution is undergoing the procedure of assessing compliance with the requirements of the directives and the harmonized standards of the European Union for entering the international market.

Kirill Tishin, Investment Director of the NTI Venture Fund managed by Kama Flow: "Today, the use of artificial intelligence in medicine is one of the most attractive investment areas, and medical images are the area where artificial intelligence is already actively used. Considering this area for investment in 2020, we have thoroughly analyzed the projects and teams in Russia that have worked in the field of radiology. Among the many companies, Celsus immediately draws attention to the maturity of approaches, technological development, quality of the final product, understanding of market needs – not every company can boast of this. We are confident that the registration of Celsus as a medical device in the highest risk class is a real breakthrough that will open up broad prospects for the explosive growth of the Russian market for the use of artificial intelligence in medicine."